Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Celltrion, Inc.

http://www.celltrion.com

Latest From Celltrion, Inc.

Coronavirus Update: Pfizer/BioNTech Commit 500m Doses For US Donations

The US obtained access to doses that it will donate to low- and low-middle-income countries, Merck & Co. is lining up government purchases of its Phase III drug, and Ocugen will submit a BLA in the US rather than pursue an EUA for Bharat's vaccine. Plus progress and setbacks for COVID-19 therapeutics. 

Coronavirus COVID-19 Vaccines

Bio Korea: R&D Strategies To Tackle Global COVID-19 Market

The Bio Korea meeting included a discussion around the challenges faced by Korean developers of COVID-19 therapies and vaccines and how they should approach the global market. Cooperation and production technology will be key.

South Korea Coronavirus COVID-19

What Will Drive Korean Pharma's Next Decade Of Growth?

A recent event in South Korea heard one prominent investor advise South Korean pharma firms to sharply increase their new drug R&D and seek direct entry into global markets, rather than pursuing licensing deals for growth

South Korea Deals

Celltrion Eyes Remsima SC Launches In Canada And Australia

While Celltrion has delivered an unimpressive first quarter of 2021, the company has pointed to plans to launch high-margin products in new markets. The Korean firm said that it was looking to launch its subcutaneous Remsima SC infliximab formulation in Canada and Australia in 2021, while it is also aiming to launch its Yuflyma (adalimumab) in more than 70% of the EU adalimumab market.

Approvals Biosimilars
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
    • OTC, Consumer
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Other Names / Subsidiaries
    • Bio CDMO
    • Celltrion Healthcare Hungary Kft
UsernamePublicRestriction

Register